- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd stock price live, this page displays NASDAQ URGN stock exchange data. View the URGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the UroGen Pharma Ltd real time stock price chart below.
What Is the UroGen Pharma Ltd Stock Price Today?
The UroGen Pharma Ltd stock price today is 20.10.
What Is the Stock Symbol for UroGen Pharma Ltd?
The stock symbol for UroGen Pharma Ltd is "URGN."
What Stock Exchange Does UroGen Pharma Ltd Trade On?
UroGen Pharma Ltd is listed and trades on the NASDAQ stock exchange.
Is UroGen Pharma Ltd a Good Stock to Buy?
Determining whether UroGen Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the URGN quote. (ISIN: IL0011407140)
What Is the UroGen Pharma Ltd Stock Price Today?
The UroGen Pharma Ltd stock price today is 20.10.
What Is the Stock Symbol for UroGen Pharma Ltd?
The stock symbol for UroGen Pharma Ltd is "URGN."
What Stock Exchange Does UroGen Pharma Ltd Trade On?
UroGen Pharma Ltd is listed and trades on the NASDAQ stock exchange.
Is UroGen Pharma Ltd a Good Stock to Buy?
Determining whether UroGen Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the URGN quote. (ISIN: IL0011407140)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.95
21.62
52 wk Range
3.42
30.00
URGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.9521.62
52 wk Range
3.4230.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
URGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
35.25
Upside
+75.37%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- Form 13G UroGen Pharma Ltd. For: 14 November
- Investing.com
- UroGen Pharma CMO Schoenberg sells $145k in shares
- Investing.com
- Form 13G UroGen Pharma Ltd. For: 14 November
- Investing.com
- UroGen Pharma CMO Schoenberg sells $145k in shares
- Investing.com
- Form 144 UroGen Pharma Ltd. For: 19 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
UroGen Pharma Ltd Company Profile
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
UroGen Pharma Ltd Earnings Call Summary for Q3/2025
- UroGen Pharma reported Q3 2025 EPS of -$0.69 (vs -$0.68 forecast) and revenue of $27.48M (vs $33.19M expected), causing a 5.49% pre-market stock decline to $18.25
- Gemyto sales grew 13% year-over-year to $25.7M, while recently launched Zesturi is gaining traction with broad insurance coverage despite overall revenue missing expectations
- The company maintained its 2025 Gemyto revenue guidance of $94-98M and expects Zesturi adoption to accelerate in 2026
- Management plans to submit the UGN-103 NDA in H2 2026 with anticipated approval in 2027, expressing confidence in Zesturi becoming a standard of care
Last Updated: 2025-11-06, 12:50 p/m
Read Full TranscriptCompare URGN to Peers and Sector
Metrics to compare | URGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipURGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.7x | −0.9x | −0.5x | |
PEG Ratio | 0.28 | 0.09 | 0.00 | |
Price/Book | −8.2x | 2.6x | 2.6x | |
Price / LTM Sales | 9.7x | 8.4x | 3.3x | |
Upside (Analyst Target) | 69.2% | 71.0% | 47.1% | |
Fair Value Upside | Unlock | 13.1% | 5.8% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 35.25
(+75.37% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.69 / -0.68
Revenue / Forecast
27.48M / 33.19M
People Also Watch
FAQ
What Is the UroGen Pharma (URGN) Stock Price Today?
The UroGen Pharma stock price today is 20.10
What Stock Exchange Does UroGen Pharma Trade On?
UroGen Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for UroGen Pharma?
The stock symbol for UroGen Pharma is "URGN."
What Is the UroGen Pharma Market Cap?
As of today, UroGen Pharma market cap is 940.86M.
What Is UroGen Pharma's Earnings Per Share (TTM)?
The UroGen Pharma EPS (TTM) is -3.46.
When Is the Next UroGen Pharma Earnings Date?
UroGen Pharma will release its next earnings report on Mar 12, 2026.
From a Technical Analysis Perspective, Is URGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has UroGen Pharma Stock Split?
UroGen Pharma has split 0 times.
How Many Employees Does UroGen Pharma Have?
UroGen Pharma has 287 employees.
What is the current trading status of UroGen Pharma (URGN)?
As of Feb 15, 2026, UroGen Pharma (URGN) is trading at a price of 20.10, with a previous close of 20.21. The stock has fluctuated within a day range of 19.95 to 21.62, while its 52-week range spans from 3.42 to 30.00.
What Is UroGen Pharma (URGN) Price Target According to Analysts?
The average 12-month price target for UroGen Pharma is USD35.25, with a high estimate of USD55 and a low estimate of USD16. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +75.37% Upside potential.
What Is the URGN Premarket Price?
URGN's last pre-market stock price is 20.48. The pre-market share volume is 2,210.00, and the stock has decreased by 0.27, or 1.34%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.